The company will also present a poster on randomized Phase II data of TG4001 in combination with avelumab in the cervical cancer subgroup. The 2025 American Society of Clinical Oncology (ASCO), annual ...

Routman, during a dedicated poster session ... therapeutic vaccine (PDS0101) alone or with pembrolizumab prior to surgery or radiation therapy for locally advanced HPV associated oropharyngeal ...

The company will also present a poster on randomized Phase II data ... TG4050, the first individualized therapeutic vaccine based on the myvac® platform is the Company’s lead asset, with ...

TG4050: Updated randomized Phase I data to be presented in Rapid Oral Presentation at ASCO 2025 Dr. Simone Steiner appointed Chief Technical Officer (CTO) Business funded until the end of April 2026 ...

Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., March ...

The company will also present a poster on randomized Phase II data of TG4001 in combination ... TG4050, the first individualized therapeutic vaccine based on the myvac® platform is the Company’s lead ...

The United States has seen progress in reducing certain cancer risks, as overall smoking rates remain on a decline.

The reported noted that the decrease is alarming as HPV vaccination rates have remained “statistically unchanged” in recent years. In 2023, 61.4% of adolescents ages 13 to 17 were up-to-date ...

Royal Navy warship HMS Prince of Wales sets sail for Indo-Pacific CNN Anchor Keeps Reporting as 6.2-Magnitude Earthquake ...

The researchers are continuing to look for ways to target ecDNA, particularly hybrid ecDNA that is linked to HPV. There are also vaccines available to prevent HPV infection; these vaccines can stop ...